01121nas a2200313   4500000000100000008004100001260001300042653002600055653001900081653001900100653001600119653003300135653001100168653001200179653002100191653001700212653001800229100001500247700001200262700001400274700001600288700001000304245010600314300001000420490000700430050001800437520033800455022001400793       2013                            d  c2013 Oct10aAnti-Infective Agents10aChagas disease10aHIV Infections10aHepatitis B10aHepatitis B Surface Antigens10aHumans10aleprosy10aStrongyloidiasis10aTuberculosis10aUnited States1 aBilodeau M1 aBurns S1 aGawoski J1 aMoschella S1 aOoi W00aCo-morbid infections in Hansen's disease patients in the United States: considerations for treatment.  a781-30 v89  aBILODEAU 20133 a<p>120 patients attending a Hansen's disease public health satellite clinic were evaluated for selected latent co-morbidities, consisting of strongyloidiasis, Chagas disease, hepatitis B, HIV, and tuberculosis, and potential exacerbation by immunosuppressive therapy. Implications for treatment of Hansen's disease are discussed.</p>  a1476-1645